Literature DB >> 35781885

The impact of type 2 immunity and allergic diseases in atherosclerosis.

Nieves Fernández-Gallego1,2, Raquel Castillo-González1,2,3, Nerea Méndez-Barbero4,5, Celia López-Sanz2, David Obeso6,7, Alma Villaseñor6,7, María M Escribese6, Beatriz López-Melgar8, Jorge Salamanca8, Amparo Benedicto-Buendía8, Luis Jesús Jiménez-Borreguero5,8, Borja Ibañez5,9,10, Joaquín Sastre11,12, María Teresa Belver13, Francisco Vega13, Carlos Blanco13, Domingo Barber6, Francisco Sánchez-Madrid1,2,5, Hortensia de la Fuente2,5, Pilar Martín1,5, Vanesa Esteban11,14, Rodrigo Jiménez-Saiz2,15,16,17.   

Abstract

Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).
© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  allergic inflammation; atherogenesis; atherosclerosis; cardiovascular disease; type 2 immunity

Year:  2022        PMID: 35781885     DOI: 10.1111/all.15426

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   14.710


  1 in total

1.  Identification of diagnostic biomarkers and therapeutic targets in peripheral immune landscape from coronary artery disease.

Authors:  Xiaoteng Feng; Yifan Zhang; Min Du; Sijin Li; Jie Ding; Jiarou Wang; Yiru Wang; Ping Liu
Journal:  J Transl Med       Date:  2022-09-05       Impact factor: 8.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.